These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 1709521)

  • 1. [Human interferons: biological and clinical promises and premises].
    Jasmin C
    Schweiz Med Wochenschr; 1991 Mar; 121(13):463-6. PubMed ID: 1709521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant application of interferons.
    el Kassas H; Kirkwood JM
    Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
    Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferons].
    Pape GR
    Schweiz Rundsch Med Prax; 1992 Sep; 81(36):1039-40. PubMed ID: 1384099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
    Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
    Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferons: physiology, pharmacology and pharmacotherapeutic perspectives].
    Billiau A
    J Pharmacol; 1983; 14 Suppl 3():105-16. PubMed ID: 6200731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons in oncology.
    Woll PJ; Pettengell R
    Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon: an early evaluation.
    McCredie KB; Moore MS
    J Indiana State Med Assoc; 1980 Sep; 73(9):576-8. PubMed ID: 6158538
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interferons in the therapy of solid tumors].
    Tomao S; Mozzicafreddo A; Raffaele M; Romiti A; Papò MA; Campisi C
    Clin Ter; 1995; 146(8-9):491-502. PubMed ID: 8536432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-viral proteins: from interferon alpha to its receptor].
    Chieux V; Hober D; Chehadeh W; Wattr P
    Ann Biol Clin (Paris); 1999 May; 57(3):283-90. PubMed ID: 10377478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update on the use of interferons in clinical practice].
    Lauta VM
    Clin Ter; 1995; 146(6-7):393-448. PubMed ID: 7586995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in interferon therapy.
    Tossing G
    Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon system in viral hepatitis].
    Lisker Melman M
    Rev Invest Clin; 1990 Jul; 42 Suppl():92-6. PubMed ID: 19256144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons].
    Cazzola M; Pedrazzoli P; Bergamaschi G; Buonanno C; Cuomo A; D'Uva R; Ponchio L; Rosti V; Zappone E; Ascari E
    Haematologica; 1990; 75 Suppl 4():20-7. PubMed ID: 2127411
    [No Abstract]   [Full Text] [Related]  

  • 17. The antitumor effects of interferon: a personal history.
    Gresser I
    Biochimie; 2007; 89(6-7):723-8. PubMed ID: 17451861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferons as potential adjuvants in prophylactic vaccines.
    Toporovski R; Morrow MP; Weiner DB
    Expert Opin Biol Ther; 2010 Oct; 10(10):1489-500. PubMed ID: 20836750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression.
    Poynard T
    Eur Cytokine Netw; 1997 Sep; 8(3):319-20. PubMed ID: 9346374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.